7 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 7 of 7 clinical reviews.
A clinician-level guide to managing adverse events with PCSK9 inhibitors (evolocumab, alirocumab, inclisiran), covering injection-site reactions, musculoskeletal complaints, neurocognitive concerns, and step-by-step protocols for FH and post-ACS patients.
A complete prescriber-level guide to PCSK9 inhibitor drug classes, FDA-approved agents, clinical evidence, prescribing criteria, and step-by-step prior authorization strategies for evolocumab and alirocumab.
A complete drug-drug interaction table for PCSK9 inhibitors (evolocumab, alirocumab, inclisiran), plus class pharmacology, dosing, and prescribing guidance for FH and post-ACS patients.
A board-reviewed clinical guide covering the PCSK9 inhibitor drug class, prescribing criteria, lipid and safety monitoring schedules, dose adjustments, and real-world outcomes data for evolocumab and alirocumab.
A prescriber-level review of PCSK9 inhibitor use across special populations including familial hypercholesterolemia, post-ACS patients, chronic kidney disease, diabetes, elderly patients, and pregnancy, with dosing guidance and key trial data.
A prescriber-level guide to choosing between evolocumab, alirocumab, and inclisiran for FH, post-ACS, and statin-intolerant patients. Covers mechanism, dosing, trial data, payer hurdles, and a practical selection framework.
A clinician-level guide to PCSK9 inhibitor drug class review, dosing titration, tapering strategies, and prescribing algorithms for FH and post-ACS patients, prepared by the HealthRX.com Editorial Team.